Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease - 04/08/21
Doi : 10.1016/j.jaci.2021.06.019
Kathleen M. Buchheit, MD a, ⁎ 
, Tanya M. Laidlaw, MD a, Joshua M. Levy, MD, MPH b
, Tanya M. Laidlaw, MD a, Joshua M. Levy, MD, MPH b a Department of Medicine, Harvard Medical School, the Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass
b Department of Otolaryngology–Head and Neck Surgery, Emory University, Atlanta, Ga
∗Corresponding author: Kathleen M. Buchheit, MD, Brigham and Women’s Hospital, 60 Fenwood Rd, Suite 5002H, Boston, MA 02445.Brigham and Women’s Hospital60 Fenwood RdSuite 5002HBostonMA02445
Key words : Aspirin-exacerbated respiratory disease, respiratory biologic, IgE, IL-5Rα, IL-4Rα, nasal polyp, mepolizumab, benralizumab, omalizumab, dupilumab
Le texte complet de cet article est disponible en PDF.
Plan
| Supported by the National Institutes of Health (grants U19AI095219, K23AI139352, and R01HL128241) and by generous contributions from the Vinik and Kaye families. |
|
| Disclosure of potential conflicts of interest: T. Laidlaw has served on scientific advisory boards for GlaxoSmithKline, Sanofi-Genzyme, Optinose, AstraZeneca, and Regeneron. K. Buchheit has served on scientific advisory boards for AstraZeneca and GlaxoSmithKline. J. Levy has served on scientific advisory boards for Regeneron Pharmaceuticals and GlaxoSmithKline. |
© 2021
Publié par Elsevier Masson SAS.
Vol 148 - N° 2
P. 348-350 - août 2021 Retour au numéro
Article précédent
- Immunologic effects of aspirin desensitization and high-dose aspirin therapy in aspirin-exacerbated respiratory disease
- Katherine N. Cahill
- AAAAI funding opportunities
- Mitchell H. Grayson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?